Real-World Patterns of Utilization of Lenalidomide-based Triplet Regimens in FIrst RElapsed Multiple Myeloma Patients: Evidence From Medical Record Review

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07611812

Enrollment

100

Registered

2026-05-28

Start date

2021-02-04

Completion date

2025-12-31

Last updated

2026-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

First Relpase, Multiple Mieloma, Rd-base Triplet

Brief summary

To compare progression-free survival (PFS) in patients with first-relapse multiple myeloma treated with Rd-based "triplets" (Daratumumab + Rd (DaraRd) vs Carfilzomib + Rd (KRd) vs. Elotuzumab + Rd (EloRd) vs. Ixazomib + Rd (IxaRd))

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Patients with multiple myeloma (MM) at first relapse treated starting in January 2017 with RD-based triplets in accordance with current clinical practice * Age ≥18 years * Written informed consent signed by the patient

Exclusion criteria

* the patient's refusal to participate

Design outcomes

Primary

Measure	Time frame
Comparison of progression-free survival (PFS) in patients with multiple myeloma at first relapse treated with Rd-based "triplet" regimens (Daratumumab + Rd (DaraRd) vs Carfilzomib + Rd (KRd) vs Elotuzumab + Rd (EloRd) vs Ixazomib + Rd (IxaRd))	The study is expected to run for 24 months starting with the enrollment of the first patient in November 2020

Countries

Italy

Outcome results